Toledo Community Oncology Program Logo

Member Login Phone: 419-843-6147
Email: info@tcop.info

Trial Search

TCOP conducts a variety of clinical trials every year. In fact, there are over 100 trials running at any given time, each specifically focusing on a particular type of cancer research. To find out if there are current trials running, addressing a specific form of cancer, click on a cancer type in the list below.


  • Assessment Study
    • Unspecified
      • RU221501I
        • Phase III Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects with Cancer related Venous Thromboembolism
      • EAY131 (CIRB)
        • Molecular Analysis for Therapy Choice (MATCH)
  • Bladder
    • Bladder
      • S1314 (CIRB)
        • Testing the Use of the Co-Expression Extrapolation Program to Predict Response to Usual Chemotherapy in Patients with Localized, Muscle Invasive Bladder Cancer
  • Bone
    • Plasmacytoma
      • A061402 (CIRB)
        • Solitary Plasmacytoma of Bone: Randomized Phase 3 Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid vs. Zoledronic Acid after Definite Radiation Therapy
  • Brain
    • Glioblastoma
      • A221101
        • A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilĀ®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiform
      • A071102 (CIRB) - (Suspended)
        • Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
  • Breast
    • Breast
      • EA1131 (CIRB)
        • Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
      • NRG-BR003 (CIRB)
        • A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
    • Cancer Control
      • E2112 (CIRB)
        • A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
      • A011401(CIRB)
        • Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
    • HER2 Negative
      • NSABP B-55 (CIRB)
        • Randomized Double Blind Parallel Group, Placebo-Controlled, Multi-center Phase III Study to Assess the Efficacy and Safety of Olaparib Vs. Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer who Have Completed Definitive Local Treatment and Neoadjuvant and Adjuvant Chemotherapy
    • HER2+
      • RU011301I
        • Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with Human Epidermal Growth Factor Receptor 2 HER2+ Breast Cancer
    • Metastatic Breast
      • EMBRACA 673-301
        • Phase 3, Open-Label, Randomized, Parallel, 2 Arm, Multi-Center Study of Talazoparib (BMN 673) vs. Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease
    • MetastaticTriple Negative
      • S1416 (CIRB)
        • Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
  • Cancer Control
    • Cancer Control
      • E1Z11
        • A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
      • AFT-28
        • Direct Oral Anticoagulants (DOACs) vs. LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS)
  • Gastrointestinal
    • Colorectal
      • OSU 2012C0123
        • Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
      • RU021407I
        • Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer
      • ARRAY 818-302
        • Multicenter, Randomized, Open-Label, 3 Arm, Phase 3 Study of Encorafenib + Cetuximab +/- Binimetinib vs. Irinotecan/Cetuximab or Infusional -FU/Folinic Acid/Irinotecan/Cetuximab with a Safety Lead-In of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutan Metastatic Colorectal Cancer
      • BBI-608
        • Phase III Study of BBI-608 in Combination with 5FU, Leucovorin, Irontecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer
    • Metastatic Colon
      • NSABP-C-13 (ARGO)
        • Phase 3, Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer - NSABP Foundation Study
    • Pancreas
      • RTOG-0848 (CIRB)
        • Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
      • S1505 (CIRB) - (Suspended)
        • Randomized Phase II Study of Perioperative mFolfirinox vs. Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
      • S1513 (CIRB)
        • Randomized Phase II Study of 2nd Line FOLFIRI vs. Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) in Metastatic Pancreatic Cancer
    • Rectal
      • NRG-GI002 (CIRB)
        • Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
  • Genitourinary
    • Prostate
      • RTOG-0924 (CIRB)
        • Androgen Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
      • S1216 (CIRB)
        • Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
  • Head and Neck
    • Head/Neck
      • RTOG-0920 (CIRB)
        • A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
  • Hematology
    • B-Cell Lymphoma
      • E1412
        • Randomized Phase II Study of Lenalidomide R-CHOP (R2CHOP) vs R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
    • Chronic Lymphocytic Leukemia
      • PCYC-1134M
        • InForm CLL - A Disease Registry for Patients with Chronic Lymphocytic Leukemia
    • Follicular Lymphoma
      • B3281006
        • Phase 3, Randomized, Double-Blind Study, of PF-05280586 vs. Rituximab for the 1st Line Treatment of Patients with CD20-Positive, Low Tumor Burden, Follicular Lymphoma
    • Hodgkins
      • CALGB-50801
        • A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
    • Multiple Myeloma
      • S1211 - (Suspended)
        • A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
      • OSU 10115
        • Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis-----------------TCOP opened 1/9/14
      • A061202
        • Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
  • Lung
    • Lung
      • A151216 (CIRB)
        • Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
      • E4512 (CIRB)
        • Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer - Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase Fusion Protein
    • Non-Small Cell
      • ABI-007-NSCL-003
        • Randomized, Phase 3, Open-Label, Multicenter, Safety and Efficacy Study to Evaluate nab-paclitaxel as Maintenance Treatment after Induction with Nab-Paclitaxel plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer
      • A081105 (CIRB)
        • Randomized Doub le Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resectedc Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer
      • BPI-2358-103 - (Suspended)
        • Randomized Blinded Phase 3 Assessment of Second or Third Line Chemotherapy with Docetaxel and Plinabulin Compared to Docetaxel + Placebo in Patients with Advanced Non-Small Cell Lung Cancer with at Least 1 large Lung Lesion
      • EA5142 (CIRB)
        • Randomized, Phase 3 Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
      • S1507 (CIRB)
        • Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer and Progressive Disease Following One or Two Prior Systemic Therapies
    • Small Cell
      • G1T28
        • Phase 1B/2A Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive Stage Small Cell Lung Cancer Receiving Etoposide and Carboplatin Chemotherapy
  • Oral Cavity/Oropharynx
    • Oropharynx
      • GT-201 Galera
        • Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent, Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
  • Pharmaceutical - Limited Sites.
    • Non-Hodgkins Lymphoma
      • PIX306
        • Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine and Rituximab in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma who have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant----------------------TCOP opened 4/13/11
  • Skin
    • Skin Cancer
      • S1320 (CIRB)
        • Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which has Spread